Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

Humans Antineoplastic Combined Chemotherapy Protocols / therapeutic use Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung / drug therapy Lung Neoplasms / drug therapy Prospective Studies Tumor Microenvironment Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
07 2023

Historique:

received: 31 10 2022

accepted: 03 05 2023

medline: 20 7 2023

pubmed: 11 7 2023

entrez: 10 7 2023

Statut: ppublish

Résumé

Although pembrolizumab confers clinical benefit in non-small cell lung cancer (NSCLC), only a subset of patients will respond due to a heterogenous tumor microenvironment. KEYNOTE-495/KeyImPaCT is an ongoing biomarker-directed, adaptively randomized phase 2 study investigating first-line pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily), anti-CTLA-4 quavonlimab (25 mg every 6 weeks) or anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks) in advanced NSCLC. Patients were categorized by T-cell-inflamed gene expression profile (Tcell

Identifiants

DOI: 10.1038/s41591-023-02385-6 PMID: 37429923

pubmed: 37429923

doi: 10.1038/s41591-023-02385-6

pii: 10.1038/s41591-023-02385-6

doi:

Substances chimiques

Biomarkers, Tumor 0

lenvatinib EE083865G2

pembrolizumab DPT0O3T46P

Antibodies, Monoclonal, Humanized 0

Antineoplastic Agents, Immunological 0

Banques de données

ClinicalTrials.gov

['NCT03516981']

Types de publication

Randomized Controlled Trial Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1718-1727

Informations de copyright

Références

Bristol Myers Squibb. OPDIVO (nivolumab) injection, for intravenous use (US prescribing information). https://packageinserts.bms.com/pi/pi_opdivo.pdf (2022).

Genentech. TECENTRIQ (atezolizumab) injection, for intravenous use (US prescribing information). https://www.gene.com/download/pdf/tecentriq_prescribing.pdf (2022).

Merck. KEYTRUDA (pembrolizumab) injection, for intravenous use. (US prescribing information). https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf (2023).

Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819–1830 (2019).

doi: 10.1016/S0140-6736(18)32409-7 pubmed: 30955977

Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).

doi: 10.1056/NEJMoa1801005 pubmed: 29658856

Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

doi: 10.1056/NEJMoa1606774 pubmed: 27718847

Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).

doi: 10.1126/science.aar3593 pubmed: 30309915 pmcid: 6718162

Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).

doi: 10.1172/JCI91190 pubmed: 28650338 pmcid: 5531419

Ott, P. A. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318–327 (2019).

doi: 10.1200/JCO.2018.78.2276 pubmed: 30557521

Cristescu, R. et al. Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types. Clin. Cancer Res. 28, 1680–1689 (2022).

doi: 10.1158/1078-0432.CCR-21-3329 pubmed: 34965943

Herbst, R. S. et al. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. Ann. Oncol. 30, LBA79 (2019).

doi: 10.1093/annonc/mdz394.077

Aurora-Garg, D. et al. Large-scale evaluation of concordance of genomic scores in whole exome sequencing and foundation medicine comprehensive genomic platform across cancer types. J. Immunother. Cancer 7, 172 (2019).

Keefer, L. A. et al. Automated next-generation profiling of genomic alterations in human cancers. Nat. Commun. 13, 2830 (2022).

doi: 10.1038/s41467-022-30380-x pubmed: 35595835 pmcid: 9123004

Paz-Ares, L. et al. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Ann. Oncol. 30, LBA80 (2019).

doi: 10.1093/annonc/mdz394.078

Perets, R. et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann. Oncol. 32, 395–403 (2020).

doi: 10.1016/j.annonc.2020.11.020 pubmed: 33276076

Taylor, M. H. et al. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J. Clin. Oncol. 38, 1154–1163 (2020).

doi: 10.1200/JCO.19.01598 pubmed: 31961766 pmcid: 7145588

Garralda, E. et al. A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. J. Clin. Oncol. 39, 3584–3584 (2021).

doi: 10.1200/JCO.2021.39.15_suppl.3584

Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).

doi: 10.1056/NEJMoa1910231 pubmed: 31562796

Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).

doi: 10.1056/NEJMoa1801946 pubmed: 29658845 pmcid: 7193684

Cristescu, R. et al. Association between tumor mutational burden (TMB) assessed by whole-exome sequencing (WES) and outcomes of pembrolizumab (pembro) monotherapy. Cancer Res. 80, LB-261 (2020).

doi: 10.1158/1538-7445.AM2020-LB-261

Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446–454 (2018).

doi: 10.1038/nature25183 pubmed: 29364287

Wang, M., Herbst, R. S. & Boshoff, C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat. Med. 27, 1345–1356 (2021).

doi: 10.1038/s41591-021-01450-2 pubmed: 34385702

Garralda, E. et al. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open 6, 100639 (2022).

doi: 10.1016/j.esmoop.2022.100639